In consideration of the detrimental role of IL-1β in the pathophysiology of myocardial infarction and diabetic cardiomyopathy, adding canakinumab on top of statins in these patients might then provide a stronger inhibition of the IL-1β-mediated inflammatory response, with additional beneficial effects on the pathophysiology of these diseases. This evidence concerns the gene IL1B and diabetic cardiomyopathy.